Cited by 67Thyroid Disorders and TreatmentsGenomics and Rare DiseasesGrowth Hormone and Insulin-like Growth Factors

Resistance to Thyroid Hormone Alpha in an 18-Month-Old Girl: Clinical, Therapeutic, and Molecular Characteristics

Open access
van Gucht, Anja L.M., Meima, Marcel E., Zwaveling-Soonawala, Nitash, Visser, W. Edward, Fliers, Eric, Wennink, Johanna M.B., Henny, Civile, Visser, Theo J. +2 more·2016·Thyroid

Abstract

BACKGROUND: Recently, the first patients with resistance to thyroid hormone alpha (RTHα) due to inactivating mutations in the thyroid hormone receptor alpha (TRα) were identified. These patients are characterized by growth retardation, variable motor and cognitive defects, macrocephaly, and abnormal thyroid function tests. The objective was to characterize a young girl (18 months old) with a mutation in both TRα1 and TRα2, and to study the effects of early levothyroxine (LT4) treatment. METHODS: The patient was assessed clinically and biochemically before and during 12 months of LT4 treatment. In addition, the consequences of the mutation for TRα1/2 receptor function were studied in vitro. RESULTS: At 18 months of age, the patient presented with axial hypotonia, delayed motor development, severe growth retardation, and abnormally elevated triiodothyronine (T3)/thyroxine (T4) ratios. RTHα was suspected, and concomitantly a c.632A>G/p.D211G missense mutation was identified, affecting both the TRα1 and TRα2 proteins. This mutation was also found in the girl's father. LT4 treatment was started, resulting in a marked improvement of her hypotonia, motor skills, and growth. Functionally, the missense mutation led to decreased transcriptional activity of TRα1, which could be overcome by higher T3 levels in vitro. The mutant TRα1 showed a moderate dominant negative activity on wild type (WT) TRα1. In contrast, WT TRα2 and mutant TRα2 had negligible transcriptional activity and showed no dominant-negative effect over TRα1. CONCLUSIONS: This report describes the phenotype of a young RTHα patient with a mild TRα mutation before and during early LT4 treatment. Treatment had beneficial effects on her muscle tone, motor development, and growth.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1089/thy.2015.0463

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In vitro analysis of the functional defects of mutant TRα1 proteins was consistent with the phenotype-genotype correlation described above.

    “In vitro analysis of the functional defects of mutant TRα1 proteins was also consistent with the phenotype–genotype correlation described above, while all studies showed that wild-type and mutant TRα2 proteins were transcriptionally inactive and had no dominant-negative activity [67, 69, 72, 76].”

    From Thyroid diseases and bone health (2018) · cites this paper as [72]

  • THRA mutations affecting both TRα1 and TRα2 have been described.

    “More recently, THRA mutations affecting both TRα1 and TRα2 have been described [67, 69, 72, 76].”

    From Thyroid diseases and bone health (2018) · cites this paper as [72]

    No passage from our copy addresses whether the reported THRA mutation affects both TRα1 and TRα2. Searches for the two isoforms, THRA mutations, and receptor-alpha splice variants returned no relevant passage. (LLM, conf=0.70)

    Experimental — accuracy not yet measured
  • Affected children and adults with THRA mutations affecting both TRα1 and TRα2 had a variable response to T4 treatment similar to that reported in individuals with mutations affecting TRα1 alone.

    “Affected children and adults had a similar spectrum of abnormalities characteristic of the skeletal dysplasia and variable response to T4 treatment reported in individuals with mutations affecting TRα1 alone.”

    From Thyroid diseases and bone health (2018) · cites this paper as [72]

    Searches for skeletal dysplasia, variable T4 response, and comparisons with TRα1-only mutations found no matching full-text passage in our copy. The returned material was labeled Abstract and describes improvement in one girl, but does not establish variable responses across affected children and adults or the claimed comparison. (LLM, conf=0.68)

    Experimental — accuracy not yet measured
  • Affected children and adults with THRA mutations affecting both TRα1 and TRα2 had a similar spectrum of abnormalities characteristic of the skeletal dysplasia to that reported in individuals with mutations affecting TRα1 alone.

    “Affected children and adults had a similar spectrum of abnormalities characteristic of the skeletal dysplasia and variable response to T4 treatment reported in individuals with mutations affecting TRα1 alone.”

    From Thyroid diseases and bone health (2018) · cites this paper as [72]

    No passage from our indexed copy addresses whether mutations affecting both TRα1 and TRα2 produce skeletal abnormalities similar to those seen with TRα1-only mutations. Searches for TRα2, skeletal dysplasia, and related terms returned no relevant passage; the only returned text was bibliographic metadata (labelled Abstract, no page). (LLM, conf=0.72)

    Experimental — accuracy not yet measured
  • Wild-type and mutant TRα2 proteins were transcriptionally inactive and had no dominant-negative activity.

    “In vitro analysis of the functional defects of mutant TRα1 proteins was also consistent with the phenotype–genotype correlation described above, while all studies showed that wild-type and mutant TRα2 proteins were transcriptionally inactive and had no dominant-negative activity [67, 69, 72, 76].”

    From Thyroid diseases and bone health (2018) · cites this paper as [72]

    Searches for TRα2 transcriptional activity and dominant-negative effects returned no body-text passage. The only matching material was labeled Abstract, which cannot serve as evidence under the supplied rubric; the claim therefore cannot be verified from the eligible passages of our copy. (LLM, conf=0.65)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
van Gucht, A. L. M., Meima, M. E., Zwaveling-Soonawala, N., Visser, W. E., Fliers, E., Wennink, J. M. B., Henny, C., Visser, T. J., Peeters, R. P., & van Trotsenburg, A. S. P.
Affiliations
  • Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands.
  • Erasmus MC (NL)
  • Department of Pediatric Endocrinology, Emma Children's Hospital, Academic Medical Center, Amsterdam, The Netherlands.
  • Amsterdam UMC Location University of Amsterdam (NL)
  • Sint Lucas Andreas Hospital (NL)
  • Practice of Pediatric Physiotherapy, Sport Medical Center, Amsterdam, The Netherlands.
Corresponding author
Peeters, Robin P.
Venue
Thyroid
Published
2016-03
Volume
26
Issue
3
Pages
338-346
ISSN
  • 1050-7256 (ISSN-L)
  • 1557-9077
OpenAlex
W2287640117
Cited by
67
References
2
Citations by year
2026: 5 · 2025: 5 · 2024: 3 · 2023: 4 · 2022: 7 · 2021: 5 · 2020: 9 · 2019: 10 · 2018: 5 · 2017: 8 · 2016: 6
FWCI
9.73
Type
journal article
Language
en
Open access
Locations
  • Thyroid (publishedVersion)
  • PubMed (publishedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
  • Pure Amsterdam UMC (submittedVersion, other-oa)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
Keywords
thyroid hormone receptor alpha, thyroid hormone receptor alpha 1, TRα2, levothyroxine therapy, growth retardation, hypotonia, motor delay, dominant negative effect, transcriptional activity, pediatric patients
MeSH terms
Cell Line, Child Development, DNA Mutational Analysis, Female, Humans, Infant, Male, Pedigree, Phenotype, Thyroid Function Tests, Thyroxine, Transfection, Treatment Outcome, Thyroid Hormone Resistance Syndrome, Genetic Predisposition to Disease, Mutation, Missense, Thyroid Hormone Receptors alpha

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review